Schrödinger to Present at H.C. Wainwright BioConnect Conference
Get Alerts SDGR Hot Sheet
Join SI Premium – FREE
NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Conference. The pre-recorded presentation will be available on Monday, January 10, 2022, at 11:00 a.m. ET.
The “on demand” webcast can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar and will be archived for approximately seven days.
About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.
Founded in 1990, Schrödinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Twitter, or visit our blog, Extrapolations.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005453/en/
Jaren Irene Madden
Schrödinger, Inc.
[email protected]
617-286-6264
Tracy Lessor
Schrödinger, Inc.
[email protected]
617-519-9827
Source: Schrödinger, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sherritt Provides Update on Operations at its Refinery
- Zehl & Associates Named National Finalist for 2026 Elite Trial Lawyers Award in Catastrophic Injury
- Ventas Names Andrew L. Wattula EVP Outpatient Medical & Research
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Twitter, H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share